What it is
Checkpoint inhibitors block the PD-1/PD-L1 "brake" that some cancers use to hide from the immune system. They are standard of care in a growing list of cancers — lung, melanoma, esophageal and others — usually guided by biomarker testing.
Why Beijing is notable
China approved not only the global agents but several domestic PD-1 antibodies with large Chinese trial programs; competition has pushed prices 60–80% below typical Western list prices. For self-paying patients on long courses, the difference is life-changing.
Whether it fits YOUR cancer
Depends on tumor type, stage, prior treatment and biomarkers (PD-L1 expression, MSI status and others). That determination — from your pathology and records — is exactly what a written oncology second opinion provides.
Costs
Course costs vary by agent and duration and are quoted individually. A pathology re-review plus written treatment-plan opinion starts from $400.